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Fc-fusion mimetics  
H. Khalili,a,b P. T. Khaw,b and S. Brocchinia,b 
The Fc-fusion mimetic RpR 2 was prepared by disulfide bridging 
conjugation using PEG in the place of the Fc. RpR 2 displayed 
higher affinity for VEGF than aflibercept. This is caused primarily 
by a slower dissociation rate, which can prolong a drug at its site 
of action. RpRs have considerable potential for development as 
stable, organ specific therapeutics.   
To achieve effective bivalency and high affinity, the two Fabs in an 
IgG antibody are mobile and are linked together as if each Fab (or 
protein) is bound at the end of linear molecule (Figure 1). FpFs 1 are 
IgG antibody mimetics (Figure 1) designed to have enhanced 
stability and binding properties compared to IgGs. They are 
prepared from PEG-di(mono-sulfone) 3 and two antibody fragments 
(Fabs).1 Fc-based fusion proteins2 (Figure 1) are also capable of 
exploiting the therapeutic advantages of bivalency that are 
displayed by IgGs. Several Fc-fusion proteins are registered for 
clinical use3 and they will continue to offer considerable clinical 
potential because of Fc recycling, but they can be difficult to 
produce during early preclinical research and to scale for 
production.4 Fc-fusion proteins are also often prone to aggregation 
during downstream processing5 and have similar stability 
limitations as IgGs. There are therapeutic applications where the Fc 
is not needed or can cause problems.6 One area of interest is the 
use of antibody based medicines in organ specific applications such 
as the eye. In such cases, Fc recycling does not occur and effector 
function can be deleterious, especially in the treatment of 
inflammatory conditions. Improved stability is important to 
formulate more concentrated solutions to decrease the frequency 
of dose administration and improved binding properties such as 
slower dissociation rates are important for organ specific targeting. 
Scheme 1. (A) Preparation of RpR 2 from PEG-di(mono-sulfone) 
3 and two equivalents of the VEGFR1-VEGFR2 monomer 4. (B) 
Use of aflibercept to obtain the monomeric VEGFR1-VEGFR2 4 
and VEGFR1-VEGFR2-Fc 5 fragments. Proteolytic digestion of 
aflibercept with the IdeS enzyme results in the cleavage of the 
Fc to give the VEGFR1-VEGFR2 dimer 6 that after treatment 
with DTT gives the VEGFR1-VEGFR2 monomer 4 which was used 
to make RpR 2. The VEGFR1-VEGFR2 monomer 4 was also 
incubated iodoacetamide to give the thiol capped VEGFR1-
VEGFR2 fragment 7 for binding studies. 
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In an effort to further explore the potential of antibody-based 
mimetics that are made using the PEG-di(mono-sulfone) 3 (Scheme 
1A, Figure 1) we describe an Fc-fusion mimetic that we call RpR 2, 
for receptor binding region-PEG-receptor binding region.  
Aflibercept (Eylea) is a Fc-fusion protein that is used to 
treat age related macular degeneration (AMD) by binding to 
vascular endothelial growth factor (VEGF) in the back of the eye. It 
is administered by intravitreal injection directly into the eye. Fc-
fusion proteins are related to IgG antibodies in that both have an Fc 
domain. IgG antibodies have two heavy and two light chains. The 
Fc-domain comprises the C2 and C3 regions of the two heavy 
chains. Disulfide bonds exist in IgG antibodies that are between the 
heavy chains in the hinge region to separate the Fc domain from 
the hinge and Fabs. Aflibercept is a homodimer that comprises 2 
monomers of (VEGFR1-VEGFR2)-(C2-C3), referred to here as VEGFR1-
VEGFR2-Fc 5 (Scheme 1B), with disulfide bonds expected to be in 
the peptide sequence between the target binding domains 
(VEGFR1-VEGFR2) and the Fc domain (C2-C3 regions) (Figure 1).
7  
Aflibercept is glycosylated with a total molecular weight of 115 kDa, 
of which 97 kDa is due to the protein component. Each mono-
sulfone moiety in reagent 3 undergoes site-specific conjugation 
with the two cysteine thiols from a disulfide bond by a sequence of 
addition-elimination reactions to insert a stable 3-carbon 
methylene bridge between the two thiols of the original disulfide 
bond (Scheme S1, ESI).8 The thiol ether bonds in a rebridged 
disulfide bond are more stable than the original disulfide bond. To 
make the desired RpR 2 we first had to obtain the VEGFR1-VEGFR2 
fragment 4 by proteolytic digestion of aflibercept to remove the Fc 
domain (Scheme 1B).  
It was first confirmed that aflibercept migrated to an 
approximate molecular weight of about 115 kDa by SDS PAGE 
(Figure 2, lane 1). Aflibercept was then treated with dithiothreitol 
(DTT) to reduce the accessible disulfide bonds thought to exist in an 
hinge like region between the binding domain (VEGFR1-VEGFR2) and 
the Fc domain. A broad band appeared at ~55-60 kDa by SDS-PAGE 
(Figure 2, lane 2). We believe this band corresponds to the 
monomeric VEGFR1-VEGFR2-Fc 5 (Scheme 1B). Glycosylation is 
usually somewhat heterogeneous in therapeutic proteins, so we 
inferred that the broadness of the band at ~55-60 kDa was due to 
glycosylation heterogeneity. DDT was then removed using a PD-10 
column and the reduced aflibercept solution was incubated with 
Ellman’s reagent which indicated the presence of 4 accessible 
cysteine thiols in aflibercept (Figure 1S, Table 1S, ESI). This 
suggested that there are 2 cysteines in each VEGFR1-VEGFR2-Fc 5 
monomer which can form two disulfide bonds in aflibercept 
analogous to what is found in the hinge region of IgG antibodies. 
Hence it was thought possible that an RpR 2 derived from 
aflibercept could be prepared using the PEG-di(mono-sulfone) 3. If 
only one cysteine had been present in the VEGFR1-VEGFR2-Fc 5 
monomer, there are stable, mono-thiol conjugation linkers 
available9 that would have been utilised in a bifunctional reagent 
analogous to PEG-di(mono-sulfone) 3.  
Proteolytic digestion of aflibercept was then examined in 
an effort to obtain the monomeric VEGFR1-VEGFR2 fragment 4 
(Figure 3). Preliminary digestion studies of aflibercept using immo-
bilised papain yielded only difficult to characterise small peptide 
fragments. We had previously used papain to digest IgGs to obtain 
Fabs,1, 10 but recognised that proteolytic digestion of different 
antibody subclasses and motifs can be difficult to control.11   
A second proteolytic enzyme (IdeS enzyme, FabRICATOR®, 
Genovis) that can cleave an IgG at glycine-glycine bonds12 in the 
hinge reagent to give F(ab)2 was then examined. Incubation of 
aflibercept with IdeS resulted in 3 bands by SDS-PAGE (Figure 2, 
lane 3). New bands appeared at approximately 30 kDa and 60-70 
kDa. A third band at approximately 95-100 kDa in this gel was 
thought to be undigested aflibercept. The lower molecular weight 
fragment at 30 kDa, which is thought to be the cleaved Fc, and the 
band for undigested aflibercept were removed by eluting the 
digestion mixture over a column that binds to the Fc domain 
(CaptureSelect Midispin, Genovis). This provided a purified a non-Fc 
containing fragment at 60-70 kDa (Figure 2, lane 4) which was 
thought to be the VEGFR1-VEGFR2 dimer 6 (Scheme 1B).  
Incubation of VEGFR1-VEGFR2 dimer 6 with DTT caused 
this fragment to disappear to give 2 lower molecular weight frag-
ments (Figure 2, lane 5). These fragments are thought to be the de-
sired VEGFR1-VEGFR2 monomer 4 (Scheme 1). Two bands are often 
observed after reduction of Fabs that are obtained by proteolytic 
digestion. This can be due to miscleavage reactions during proteo-
lysis and may be exacerbated for aflibercept due to its difference in 
structure compared to an IgG and due to aflibercept glycosylation. 
There are five N-glycosylation sites on each monomeric VEGFR1-
VEGFR2-Fc fragment 5 which may be partially or completely glycol-
sylated. There may also be additional heterogeneity caused by 
differences in saccharide structure. 
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To prepare the RpR 2, the VEGFR1-VEGFR2 dimer 6 was 
first incubated with DTT for 30 minutes to give the VEGFR1-VEGFR2 
monomer 4 (Scheme 1B). The reaction mixture was carefully eluted 
over a PD-10 column to remove the DTT while avoiding disulfide 
reformation, and then the PEG di(mono-sulfone) reagent 3 (derived 
from a 10 kDa PEG precursor) was added to the solution of the 
monomeric VEGFR1-VEGFR2 4. Incubation of the reaction mixture 
for 3 h (Figure 2S, lane 1, ESI) was then followed by purification by 
size exclusion chromatography (Figure 2S, lanes 2-10, ESI) to give 
the purified RpR 2 which appeared in a band at approximately 70 
kDa (Figure 2, lanes 6 and 7). Two detection dyes were used, first 
coomassie blue to detect protein (lane 6) and then barium iodide to 
detect the PEG (lane 7) being conjugated to the protein. Starting 
from 0.8 mg (in 1.0 mL) of VEGFR1-VEGFR2 dimer 6, approximately 
0.16 mg (in 0.5 mL) of RpR 2 was obtained (~ 20 % yield). 
At 25˚C the purified RpR 2 displayed a solution size of 10.7 
± 0.5 nm (Pd, 0.7 ± 0.1 nm), which is similar to the starting 
aflibercept (10.2 ± 0.7 nm; Pd, 0.6 ± 0.1 nm). The FpF antibody 
mimetics 1 were also a similar solution size to the corresponding 
IgG.1 This is in stark contrast to when PEG is conjugated only at one 
terminus to a single protein where the solution size of a PEG-
protein conjugate is dominated by the random coil nature of PEG.13 
When only one terminus of PEG is conjugated to a protein, the 
other PEG terminus has considerable freedom to allow the PEG to 
maintain a large solution structure.  
As a macromolecule, the RpR has a protein at each 
terminus of the PEG scaffold, which would constrain the motion of 
the PEG, so this Fc-fusion mimetic is analogous to an A-B-A block 
copolymer
 
where it is known that the two functionalised end blocks 
linear polymers functionalised at both ends can self-associate.14 The 
dimeric VEGFR1-VEGFR2 fragment 6 also displayed a solution size of 
10.03 ± 0.1 nm (Pd, 0.7 ± 0.1 nm) which is similar to both aflibercept 
and RpR 2. Interestingly, when the VEGFR1-VEGFR2 fragment 6 was 
treated with DTT and the cysteine thiols were blocked with 
iodoacetamide, the cysteine thiol-capped monomeric VEGFR1-
VEGFR2 fragment 7 (Scheme 1B) displayed a solution size of 7.2 ± 
0.4 nm (Pd, 0.7 ± 0.1 nm). Although the dimer 6 is twice the 
molecular weight of the VEGFR1-VEGFR2 monomer 7, its solution 
sizeits size in solution is only about 40% larger suggesting that there 
may be some non-covalentis intramolecular association of 
thebetween each of the  VEGFR1-VEGFR2 domains monomers within 
the dimer 6.  
The binding properties of the RpR 2 and aflibercept were 
then evaluated by surface plasmon resonance (Biacore) to 
determine the affinity (KD), and the rate constants of association 
(ka) and dissociation (kd) (Table 1). Vascular endothelial growth 
factor-165 (VEGF165), which is a ligand for aflibercept, was 
immobilised at a density to minimise or prevent rebinding events 
(91 RU).1, 15 The dissociation rate (kd) for the RpR 2 was slower than 
what was observed with aflibercept. Interestingly, the ka appeared 
to be slightly faster in RpR 2 compared to aflibercept. This is in 
contrast to what was previously observed for anti-VEGF FpF which 
had a slower association rate than the precursor IgG antibody.1 
However it was the decreased kd of RpR 2 that appeared to be the 
dominating factor to cause the improved affinity of RpR 2 compared 
to aflibercept (Table 1). Representative fitting curves for aflibercept 
and RpR 2 are shown in the ESI (Figure S3, ESI). 
Exploiting reduced dissociation rates may be a viable 
strategy to increase efficacy by increasing the residence time and 
mode of action within specific tissue.16 Although the reduction in kd 
for FpF 1 is also slower than the parent IgG,1 there appears to be a 
greater relative reduction in kd for the RpR 2 compared to its parent 
Fc-fusion (i.e. aflibercept). During initial dissociation steps from the 
ligand of one of the two VEGFR1-VEGFR2 domains in the RpR 2, PEG 
conformational flexibility may be more efficient for rebinding than 
the polypeptide linking the Fc domain to the VEGFR1-VEGFR2 
domain in aflibercept. This suggests there is less flexibility in the 
bivalent binding moieties in the Fc-fusion protein (aflibercept) than 
there is in an IgG (e.g. bevacizumab).   
The VEGF binding of the capped VEGFR1-VEGFR2 
monomer 7 (Figure S4, ESI) was reduced when compared to the 
VEGFR1-VEGFR2 dimer 6. This exemplified the advantages of the 
cooperative bivalent binding that is possible with (i) aflibercept, (ii) 
the dimeric VEGFR1-VEGFR2 fragment 6 and (iii) RpR 2 (Table 1). The 
similar binding properties that were observed for both the dimer 6 
and aflibercept suggests that the placement of the accessible 
disulfide bonds linking each monomer in aflibercept is important for 
the mobility of the VEGFR1-VEGFR2 binding domains. Inclusion of a 
polypeptide sequence to extend the VEGFR1-VEGFR2 receptor 
domains away from the aflibercept disulfide bonds to better 
optimise dissociation rates would be expected to make aflibercept 
less stable. Such an added polypeptide sequence to increase the 
flexibility of the VEGFR1-VEGFR2 receptor domains would invariably 
lack secondary structure in a similar way to the hinge region of IgG 
antibodies. While the hinge region in IgG antibodies provides the 
flexibility needed for cooperative and bivalent binding of both 
Fabs,17 the IgG hinge region is also vulnerable to degradation and 
disulfide scrambling.18 The stable conjugation imparted by PEG-
di(mono-sulfone) 3 and use of a PEG scaffold provides enough 
flexibility of the VEGFR1-VEGFR2 binding moieties to potentially 
maximise both association and dissociation rates that could be 
important in the development of new therapeutics.   
Sample 
ka 
(×10
5
) M
-1
s
-
1 
kd 
(× 10
-4
) s
-1 
KD 
(kd/ka) nM 
Aflibercept 0.88 4.20 4.78 
(VEGFR1-VEGFR2)2 6 1.20 5.20 4.30 
RpR 2 1.13 1.90 1.71 
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RpR 2 was then evaluated in vitro using a human umbilical 
vein endothelial cell (HUVEC) co-culture (Figure 3). This assay 
measures the migration and the formation of an anastomosing 
network that is characterised by tubule and junction formation 
during HUVEC proliferation. These processes are characteristic for 
angiogenesis and are often a good in vitro measurement for 
angiogenesis.19 RpR 2 and aflibercept were incubated with VEGF165 
at different molar ratios of 3.0, 1.5, 0.5 for 2 hours at 370C prior to 
incubation with HUVECs. VEGF165 and anti-mouse TNF-α IgG were 
used for positive controls. Images were obtained after fixing 
HUVECs with an anti-CD31 antibody to differentiate between the 
endothelial tubular network and non-endothelial structures of 
similar apparent morphology (Figure 3A). These images suggest that 
both aflibercept and RpR 2 have similar anti-angiogenic properties. 
Quantification of tubule (Figure S5, ESI) and junction formation 
(Figure 3B) (AngioSys Image Analysis Software, TCS Cellworks Ltd.) 
showed that the formation of these structures were similarly 
inhibited in a concentration dependent manner by both RpR 2 and 
aflibercept.  
To summarise, a new antibody Fc-fusion mimetic called 
an RpR was prepared. Aflibercept is a clinically used Fc-fusion 
protein that targets VEGF was used for these studies. Proteolytic 
digestion of aflibercept followed by incubation with DTT provided 
the monomeric VEGFR1-VEGFR2 domain 4 that was then conjugated 
to the PEG-di(mono-sulfone) 3 by disulfide bridging conjugation to 
give the anti-VEGF RpR 2. The strategy to proteolytically digest 
aflibercept provided the means to compare the properties of the 
RpR Fc-fusion mimetic 2 with aflibercept. The solution size of RpR 2 
and its in vitro activity are comparable to aflibercept. Of most 
interest is that binding studies show that RpR 2 has higher affinity 
for VEGF compared to aflibercept primarily due to a slower 
dissociation rate. Antibody based mimetics such as RpR 2 have 
potential for development as stable, organ specific therapeutics.   
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Disulfide bridging PEG conjugation. 
The use of bis-alkylation for conjugation can be utilised for the site-specific conjugation of 
the two cysteine thiols derived from a native disulfide.1 Conjugation is thought to occur by an 
addition-elimination pathway shown in Scheme S1. This approach to site-specific 
conjugation was initially developed for site-specific PEGylation and has now been shown to 
be a valuable approach for the development of antibody drug conjugates2 as well as the 
fabrication of FpFs3 and now RpRs. PEG mono-sulfone reagents 8 have also been shown to 
undergo site-specific conjugation to histidine tags.4 
 
Scheme S1. The mono-sulfones 8 are latently crossed functionalised reagents capable of sequential 
and interactive addition-elimination reactions capable of bis-alkylation. In the case of disulfides, first 
the cysteine thiols are liberated by reduction (e.g. TCEP1b or DTT) and then conjugation involves (i) a 
first thiol addition to the mono-sulfone reagent 8, (ii) sulphinic acid elimination to generate a second 
double bond, and (iii) a second thiol addition.  
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Experimental details 
Preparation of sodium phosphate buffer (20 mM, pH 7.4) with EDTA (10 mM) 
To a 500 mL Fisher bottle with a magnetic stir bar was added sodium phosphate monobasic, 
NaH2PO4 (600 mg, Mw=119.98 g/mol, 5 moles), EDTA (931 mg Mw = 372.24 g/mol, 2.5 
mmole) and distilled water (250 mL, Type 1, 18 mΩ resistance). The solution was gently 
stirred until homogeneous and using a pH meter, the pH was carefully adjusted to 7.4 by the 
dropwise addition of sodium hydroxide (1 N). 
Dithiothreitol Dithriothreitol reduction of aflibercept to give VEGFR1-VEGFR2 -Fc 5 
“Dithriothreitol” with “Dithiothreitol”Into an eppendorf (1.5 mL) was added dithiothreitol (DTT, 
1.0 mg) and a solution of aflibercept (1.0 mg, 1.0 mL in the sodium phosphate buffer (20 
mM, pH 7.6) with EDTA (10 mM).  This solution was allowed to incubate at ambient 
temperature without shaking for 30 min. The monomer VEGFR1-VEGFR2-Fc fragment 5 was 
obtained after removal of DTT by PD-10 column by buffer exchanging into a sodium 
phosphate buffer (20 mM, pH 7.6) with EDTA (10 mM). A representative procedure to 
remove the DTT from a volume of 1.0 mL of reaction mixture using a PD-10 column was as 
follows: first a PD-10 column was equilibrated by allowing solutions of sodium phosphate 
buffer (20 mM, pH 7.6, 25 mL) with EDTA (10 mM) to elute through the column. Then, the 
protein solution with DTT (1.0 mL) was loaded onto the equilibrated PD-10 column.  After 
this, 1.5 mL sodium phosphate buffer (20 mM, pH 7.6) with EDTA (10 mM) was added to the 
PD-10 column and allowed to elute. Finally, the protein solution was recovered by addition of 
a 3.3 mL sodium phosphate buffer (20 mM, pH 7.6) with EDTA (10 mM) to the PD-10 
column. 
Ellman’s reagent (4.0 mg, DTNB, 5,5-dithio-bis-(2-nitrobenzoic acid; Thermo Fisher, 
cat. no. 225820) was dissolved in 1.0 mL of the reaction buffer (sodium phosphate buffer (20 
mM), EDTA (1.0 mM), pH 8.0). Cysteine standard solutions in the reaction buffer were 
prepared using cysteine hydrochloride monohydrate at the concentrations of 0.25, 0.5, 0.75, 
1.0, 1.25 and 1.5 mM.  A blank solution with no cysteine hydrochloride was also prepared.  
An aliquot of each standard concentration (250 µL) and blank was added to a solution 
comprised of the Ellmans reagent (50 µL) and the reaction buffer (2.5 mL). These mixtures 
were allowed to incubate for 15 min at ambient temperature and then the absorbance of 
each solution was measured (412 nm) relative to blank.  
The concentration of thiols in the sample solution (0.2 mL) was first calculated. Then, 
the value was divided by the concentration of protein in the sample solution to obtain the 
number of thiols in the solution. No free thiol was observed with native aflibercept. However, 
monomeric VEGFR1-VEGFR2-Fc fragment 5 (4.5 x 10
-3 mM) after DTT treatment displayed 
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an absorbance of 0.054 at 412 nm. This was equal to 4 free thiols for the starting aflibercept 
indicating the presence of two interchain disulfide bonds.  
 
Figure 1S. The calibration curve for cysteine standard solutions at 412 nm for the Ellmans assay. 
Samples Absorbance  
Cysteine 0.0 mM (blank) 0.005 
Cysteine 0.25 mM 0.263 
Cysteine 0.5 mM 0.51 
Cysteine 0.75 mM 0.699 
Cysteine 1.0 mM 0.998 
Cysteine 1.25 mM 1.18 
Cysteine 1.5 mM 1.32 
Aflibercept (9 x 10-3 mM) 0.031 
Reduced-aflibercept (4.5 x 10-3 mM) 0.054 
Table 1S. Absorption at 412 nm for aflibercept before and after DTT reduction in the presence of 
Ellman’s reagent. 
Proteolytic digestion of aflibercept to prepare the dimeric VEGFR1-VEGFR2 fragment 6 
Immobilised IdeS enzyme (FabRICATOR®, FragIT MidiSpin, Genovis; Cat no A0-FR6-100) 
was used for the proteolytic digestion of aflibercept. The top lid and the bottom cap of the 
FragIT MidiSpin column was removed and the column centrifuged at 100 × g for 1.0 min to 
remove storage buffer. The column was then equilibrated with cleavage buffer (2.5 mL; 50 
mM sodium phosphate, 150 mM NaCl, pH 6.6) and centrifuged twice at 100 × g for 1 min. 
The bottom of the column was then capped and secured with parafilm to stop any leakage. 
Aflibercept (6 mg in 1.0 mL cleavage buffer) was then added to the column and the top lid 
was sealed. The aflibercept digestion solution was incubated on the column for 30 min at 
ambient temperature by end-over-end mixing. After 30 min, the top lid and bottom cap were 
removed and spin column was centrifuged at 100 × g for 1.0 min. The column was then 
washed with cleavage buffer (1.0 mL) and centrifuged at 100 × g for 1.0 min. 
The digestion mixture and washing solutions were combined. Analysis by SDS-
PAGE confirmed the presence of the VEGFR1-VEGFR2 dimer 6, which was then purified by 
y = 0.8897x + 0.0217
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elution over a CaptureSelect MidiSpin column (Genovis, Cat no A2-FR2-100). The column is 
packed with a multi species Fc affinity matrix on agarose beads that binds Fc containing 
fragments from solution. The CaptureSelect column was first pre-equilibrated with binding 
buffer (3.0 mL; 10mM sodium phosphate, 150mM NaCl, pH 7.4) and then centrifuged at 200 
× g for 1.0 min to remove the binding buffer. The pooled aflibercept digestion solution was 
then added to the CaptureSelect column, which was then sealed and the column was 
allowed to incubate for 30 min at ambient temperature with end-over-end mixing. The 
column was then centrifuged at 200 × g for 1 min and the first fraction containing the purified 
VEGFR1-VEGFR2 dimer 6 was obtained. The column was then washed with binding buffer 
(1.0 mL) and then centrifuged (200 × g, 1.0 min) two times to ensure as much VEGFR1-
VEGFR2 dimer 6 could be recovered as possible.  The solutions containing the purified 
VEGFR1-VEGFR2 dimer 6 were then combined and analysed by SDS-PAGE and the 
concentration was determined using a micro BCA assay. From 6 mg of aflibercept, it was 
possible to obtain 2 mg of VEGFR1-VEGFR2 dimer 6.  Removal of Fc containing species 
from the CaptureSelect column was achieved using glycine buffer (pH 1.5). 
Preparation of RpR 2 general procedure 
Dimeric VEGFR1-VEGFR2 fragment 6 (0.8 mg/mL, 1.0 mL PBS pH 7.3) was treated with 
DDT (1.0 mg, 6.0 mM) without shaking for a 30 min period at ambient temperature to give 
VEGFR1-VEGFR2 monomer 4. The DDT reaction mixture was buffer exchanged (sodium 
phosphate buffer (20 mM), EDTA (10 mM) and pH 7.6) to remove the DDT using a PD-10 
column. To a solution of monomeric VEGFR1-VEGFR2 4 (3.3 mL, 0.24 mg/mL) was added 
0.9 equivalents the PEG di(mono-sulfone) reagent 3 (0.12 mg PEG reagent 3, 10 kDa) and 
the reaction mixture was incubated for 12 h at 4 0C without shaking. The reagent 3 was 
prepared as previously described.3 RpR 2 was then purified from the reaction mixture by 
size exclusion chromatography (SEC), which was conducted using a superpose 12 HR 
10/30 size exclusion column (30 µm particle size) and phosphate buffered saline (PBS) 
solution (NaCl (0.16 M), KCl (0.003M), Na2HPO4 (0.008M) and KH2PO4 (0.001M) at pH 7.3).  
A run time of 40 min using a flow rate of 1.0 mL/min were applied. Fractions (1.0 mL) were 
collected and analysed using SDS-PAGE (Figure 2S, lanes 2-10). The SEC fractions 
containing the desired RpR 2 (Figure 2S, lanes 4-6) were pooled and concentrated to 1.0 
mL solution using VIVA-SPIN. The concentration of RpR 2 was then determined by by 
micro-BCA assay. From 0.8 mg of starting VEGFR1-VEGFR2 dimer 6, 0.2 mg of purified RpR 
fragment 2 was obtained. 
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Figure 2S. SDS-PAGE gels of reaction 
mixture between VEGFR1-VEGFR2 dimer 
6 (1.0 mg/mL) and PEG reagent 3 (1 eq, 
10 kDa), purification of RpR using size-
exculsion chromatography (SEC); Novex 
Bis-Tris 4-12% gel stained with colloidal 
blue for protein. M: standard protein 
markers, Lane 1: Conjugation reaction 
mixture,  Lanes 2-10: SEC fractions for 
RpR purification. 
Thiol-capped VEGFR1-VEGFR2 fragment 7 
Iodoacetimide (18 mM, 5.5 mg) was added to a solution of VEGFR1-VEGFR2 monomer 4 
(0.35 mg, 1.65 mL).  After incubation for 1.0 h at ambient temperature in the dark, the 
solution was then buffer exchanged to the sodium phosphate buffer (20 mM), EDTA (10 
mM) and pH 7.6 using a PD-10 column to remove iodoacetamide species.  
Determination of the solution size of RpR 2 by static light scattering 
The DynoPro plate reader II (Wyatt technology) measures the size (hydrodynamic radius) 
and size distribution of the protein from a 0.5 nm to 1000 nm range using a dynamic light 
scattering (DLS) method. Samples (aflibercept, VEGFR1-VEGFR2 dimer 6, thiol capped 
VEGFR1-VEGFR2 fragment 7 and RpR 2) were prepared at concentration of 0.3 mg/mL 
using PBS buffer which was passed through a 0.2 µm filter. Into each well of the 384 well 
plate (Corning, cat no 23714026), 30 µL of sample was added (three replicates for each 
sample) and analysed at 25 0C.  
Binding properties of RpR 2 determined by surface plasmon resonance 
BIAcore X-100 (BIAcore, GE healthcare LTD Amersham) was used for binding affinity 
studies of the aflibercept, VEGFR1-VEGFR2 dimer 6 and RpR 2. Human recombinant 
VEGF165 (38 kDa Mw) was immobilised on CM3 chip at an immobilisation level of 91 RU 
using standard carbodiimide-mediated coupling (NHS/EDC, 50/50) and ethanolamine (pH 
8.5). Samples were prepared in HBS-EP running buffer (10 mM HEPES, pH 7.4, 150 mM 
NaCl, 3.0 mM EDTA, 0.005% surfactant P20). All kinetic measurements were conducted at 
25 0C at a flow rate of 30 µL/min with an association time of 180 s and dissociation time of 
1200 s. Chip regeneration was accomplished by exposure to 10.0 mM glycine−HCl (pH 2.0) 
for 30 s. Double-referencing was performed to account for bulk effects caused by changes in 
the buffer composition or nonspecific binding. Data were evaluated with BIAevaluation 
software (version 2.1) and the best fit (lowest χ2) was obtained using a 1:1 binding model. 
The sensorgram was fitted globally over the association and dissociation phases. 
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Equilibrium dissociation constants (affinity) were calculated from the rate constants (KD = kd 
/ka). Figure 3S show representative fitting curves for aflibercept and RpR using 1:1 binding 
model.  
(A) Aflibercept 
  
(B) RpR 2 
 
Figure S3. Representative fitting curves for aflibercept and RpR 2.  
There are parameters such as the tc, Chi2 and U-value which help to assess the fitting 
model. The Chi2 is the sum of the squared error between the fitted curve and experimental 
curve. This number should be as small as possible (less than 2 and even less than 1). The 
parameter which represents the effect of mass transport limitation is tc. If the tc value is be-
tween 107 to 109, then there is a mass transport limitation. The U-value is a parameter that 
represents the uniqueness of the calculated rate constant and Rmax. Lower U-values indicate 
greater confidence in the results. A high value (above 25) indicates that the reported kinetic 
rate constants are not useful.  
The binding chart (Figure S4) for VEGFR1-VEGFR2 dimer 6 and VEGFR1-VEGFR2 
monomer 7 illustrates the increased binding in aflibercept due to bivalency.  
  
 
 
 
Figure S4. Binding chart for 
VEGFR1-VEGFR2 dimer 6 
and thiol-capped monomeric 
VEGFR1-VEGFR2 7. 
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2
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2
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Functional activity of RpR 2 using in vitro anti-angiogenesis co-culture assay 
A HUVEC co-culture assay (V2a kit, cat no ZHA-4000, TCS Cellworks Ltd.) was used 
according to the manufacturer’ s instructions. Test samples were sterilized using filter (0.22 
µm) and diluted in growth medium to their final required concentrations and added to each 
well (0.5 mL per well) of 24-well plate. The concentration of VEGF165 used was 10 ng/mL in 
each well and the concentrations of the RpR 2 were normalized for their protein molecular 
weights. For example, for molar ratios of 3:1, 1.5:1, and 0.5:1 of sample to VEGF, in well 
concentrations of 0.06, 0.03, and 0.01 µg/mL of RpR 2, and 0.08, 0.04 and 0.015 µg/mL of 
aflibercept were required. The samples were pre-incubated with hVEGF165 for 2 h at 37 
0C 
before addition to the cells. As negative control, designated wells were treated with medium 
only (no VEGF) and for positive controls treated with only VEGF (10 ng/mL) and VEGF (10 
ng/mL) with anti-mouse anti-TNF IgG (0.08 µg/mL). Triplicate wells were prepared for each 
test environment. The assay plate was then placed in a humidified incubator (37 0C, 5% 
CO2). Media was replaced with fresh culture media containing the test samples on days 4, 7, 
and 9. On day 10, cells were fixed (ice-cold 70% ethanol; 0.5 mL per well). Cells were first 
exposed to mouse anti-human CD31 primary antibody (1:400 dilution, 0.5 mL per well, 60 
min at 37 0C), followed by alkaline phosphatase-linked goat anti-mouse secondary antibody 
(1:500 dilution, 0.5 mL per well, 60 min at 37 0C). Cells were then rinsed and permanently 
stained for CD31 using insoluble 5-bromo-4-chloro-3-indolylphosphate/nitroblue-tetrazolium 
salt. Plates were air-dried and photomicrographs were taken using an upright microscope. 
The images were subsequently analyzed using AngioSysn (AngioSys Image Analysis 
Software, TCS Cellworks Ltd) software to calculate the number of junctions and tubules 
(Figure S5) formed in each well. 
 
Figure S5.  Tubule formation observed for medium alone, medium + VEGF, Anti-mouse TNF-a IgG + 
VEGF, aflibercept + VEGF and RpR + VEGF. Ratios are the amount of test compound to VEGF. 
VEGF was present at a fixed concentration of 10 ng/mL. 
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Fc-fusion	mimetics		
H.	Khalili,a,b	P.	T.	Khaw,b	and	S.	Brocchinia,b	
The	 Fc-fusion	mimetic	 RpR	 2	was	 prepared	 by	 disulfide	 bridging	
conjugation	 using	 PEG	 in	 the	 place	 of	 the	 Fc.	 RpR	 2	 displayed	
higher	affinity	 for	VEGF	 than	aflibercept.	 This	 is	 caused	primarily	
by	a	slower	dissociation	rate,	which	can	prolong	a	drug	at	its	site	
of	 action.	 RpRs	 have	 considerable	 potential	 for	 development	 as	
stable,	organ	specific	therapeutics.			
To	achieve	effective	bivalency	and	high	affinity,	the	two	Fabs	in	an	
IgG	antibody	are	mobile	and	are	 linked	together	as	 if	each	Fab	(or	
protein)	is	bound	at	the	end	of	linear	molecule	(Figure	1).	FpFs	1	are	
IgG	 antibody	 mimetics	 (Figure	 1)	 designed	 to	 have	 enhanced	
stability	 and	 binding	 properties	 compared	 to	 IgGs.	 They	 are	
prepared	from	PEG-di(mono-sulfone)	3	and	two	antibody	fragments	
(Fabs).1	 Fc-based	 fusion	 proteins2	 (Figure	 1)	 are	 also	 capable	 of	
exploiting	 the	 therapeutic	 advantages	 of	 bivalency	 that	 are	
displayed	 by	 IgGs.	 Several	 Fc-fusion	 proteins	 are	 registered	 for	
clinical	 use3	 and	 they	 will	 continue	 to	 offer	 considerable	 clinical	
potential	 because	 of	 Fc	 recycling,	 but	 they	 can	 be	 difficult	 to	
produce	 during	 early	 preclinical	 research	 and	 to	 scale	 for	
production.4	Fc-fusion	proteins	are	also	often	prone	to	aggregation	
during	 downstream	 processing5	 and	 have	 similar	 stability	
limitations	as	IgGs.	There	are	therapeutic	applications	where	the	Fc	
is	 not	needed	or	 can	 cause	problems.6	One	area	of	 interest	 is	 the	
use	of	antibody	based	medicines	in	organ	specific	applications	such	
as	 the	eye.	 In	such	cases,	Fc	 recycling	does	not	occur	and	effector	
function	 can	 be	 deleterious,	 especially	 in	 the	 treatment	 of	
inflammatory	 conditions.	 Improved	 stability	 is	 important	 to	
formulate	more	 concentrated	 solutions	 to	decrease	 the	 frequency	
of	 dose	 administration	 and	 improved	 binding	 properties	 such	 as	
slower	dissociation	rates	are	important	for	organ	specific	targeting.	
Scheme	1.	(A)	Preparation	of	RpR	2	from	PEG-di(mono-sulfone)	
3	and	 two	equivalents	of	 the	VEGFR1-VEGFR2	monomer	4.	 (B)	
Use	of	aflibercept	 to	obtain	 the	monomeric	VEGFR1-VEGFR2	4	
and	 VEGFR1-VEGFR2-Fc	 5	 fragments.	 Proteolytic	 digestion	 of	
aflibercept	with	the	IdeS	enzyme	results	in	the	cleavage	of	the	
Fc	 to	 give	 the	 VEGFR1-VEGFR2	 dimer	 6	 that	 after	 treatment	
with	DTT	gives	the	VEGFR1-VEGFR2	monomer	4	which	was	used	
to	 make	 RpR	 2.	 The	 VEGFR1-VEGFR2	 monomer	 4	 was	 also	
incubated	 iodoacetamide	 to	 give	 the	 thiol	 capped	 VEGFR1-
VEGFR2	fragment	7	for	binding	studies.	
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In	 an	 effort	 to	 further	 explore	 the	 potential	 of	 antibody-based	
mimetics	that	are	made	using	the	PEG-di(mono-sulfone)	3	(Scheme	
1A,	Figure	1)	we	describe	an	Fc-fusion	mimetic	that	we	call	RpR	2,	
for	receptor	binding	region-PEG-receptor	binding	region.		
Aflibercept	 (Eylea)	 is	 a	 Fc-fusion	 protein	 that	 is	 used	 to	
treat	 age	 related	 macular	 degeneration	 (AMD)	 by	 binding	 to	
vascular	endothelial	growth	factor	(VEGF)	in	the	back	of	the	eye.	It	
is	 administered	 by	 intravitreal	 injection	 directly	 into	 the	 eye.	 Fc-
fusion	proteins	are	related	to	IgG	antibodies	in	that	both	have	an	Fc	
domain.	 IgG	 antibodies	 have	 two	 heavy	 and	 two	 light	 chains.	 The	
Fc-domain	 comprises	 the	 C2	 and	 C3	 regions	 of	 the	 two	 heavy	
chains.	Disulfide	bonds	exist	in	IgG	antibodies	that	are	between	the	
heavy	 chains	 in	 the	 hinge	 region	 to	 separate	 the	 Fc	 domain	 from	
the	 hinge	 and	 Fabs.	 Aflibercept	 is	 a	 homodimer	 that	 comprises	 2	
monomers	of	(VEGFR1-VEGFR2)-(C2-C3),	referred	to	here	as	VEGFR1-
VEGFR2-Fc	 5	 (Scheme	 1B),	 with	 disulfide	 bonds	 expected	 to	 be	 in	
the	 peptide	 sequence	 between	 the	 target	 binding	 domains	
(VEGFR1-VEGFR2)	 and	 the	 Fc	 domain	 (C2-C3	 regions)	 (Figure	 1).
7		
Aflibercept	is	glycosylated	with	a	total	molecular	weight	of	115	kDa,	
of	 which	 97	 kDa	 is	 due	 to	 the	 protein	 component.	 Each	 mono-
sulfone	 moiety	 in	 reagent	 3	 undergoes	 site-specific	 conjugation	
with	the	two	cysteine	thiols	from	a	disulfide	bond	by	a	sequence	of	
addition-elimination	 reactions	 to	 insert	 a	 stable	 3-carbon	
methylene	 bridge	 between	 the	 two	 thiols	 of	 the	 original	 disulfide	
bond	 (Scheme	 S1,	 ESI).8	 The	 thiol	 ether	 bonds	 in	 a	 rebridged	
disulfide	bond	are	more	stable	than	the	original	disulfide	bond.	To	
make	the	desired	RpR	2	we	first	had	to	obtain	the	VEGFR1-VEGFR2	
fragment	4	by	proteolytic	digestion	of	aflibercept	to	remove	the	Fc	
domain	(Scheme	1B).		
It	 was	 first	 confirmed	 that	 aflibercept	 migrated	 to	 an	
approximate	 molecular	 weight	 of	 about	 115	 kDa	 by	 SDS	 PAGE	
(Figure	 2,	 lane	1).	 Aflibercept	was	 then	 treated	with	dithiothreitol	
(DTT)	to	reduce	the	accessible	disulfide	bonds	thought	to	exist	in	an	
hinge	like	region	between	the	binding	domain	(VEGFR1-VEGFR2)	and	
the	Fc	domain.	A	broad	band	appeared	at	~55-60	kDa	by	SDS-PAGE	
(Figure	 2,	 lane	 2).	 We	 believe	 this	 band	 corresponds	 to	 the	
monomeric	 VEGFR1-VEGFR2-Fc	 5	 (Scheme	 1B).	 Glycosylation	 is	
usually	 somewhat	 heterogeneous	 in	 therapeutic	 proteins,	 so	 we	
inferred	that	the	broadness	of	the	band	at	~55-60	kDa	was	due	to	
glycosylation	heterogeneity.	DDT	was	then	removed	using	a	PD-10	
column	 and	 the	 reduced	 aflibercept	 solution	 was	 incubated	 with	
Ellman’s	 reagent	 which	 indicated	 the	 presence	 of	 4	 accessible	
cysteine	 thiols	 in	 aflibercept	 (Figure	 1S,	 Table	 1S,	 ESI).	 This	
suggested	 that	 there	 are	 2	 cysteines	 in	 each	 VEGFR1-VEGFR2-Fc	 5	
monomer	 which	 can	 form	 two	 disulfide	 bonds	 in	 aflibercept	
analogous	 to	what	 is	 found	 in	 the	 hinge	 region	 of	 IgG	 antibodies.	
Hence	 it	 was	 thought	 possible	 that	 an	 RpR	 2	 derived	 from	
aflibercept	could	be	prepared	using	the	PEG-di(mono-sulfone)	3.	 If	
only	 one	 cysteine	 had	 been	 present	 in	 the	 VEGFR1-VEGFR2-Fc	 5	
monomer,	 there	 are	 stable,	 mono-thiol	 conjugation	 linkers	
available9	 that	would	 have	 been	 utilised	 in	 a	 bifunctional	 reagent	
analogous	to	PEG-di(mono-sulfone)	3.		
Proteolytic	digestion	of	aflibercept	was	then	examined	in	
an	 effort	 to	 obtain	 the	 monomeric	 VEGFR1-VEGFR2	 fragment	 4	
(Figure	3).	Preliminary	digestion	studies	of	aflibercept	using	 immo-
bilised	 papain	 yielded	 only	 difficult	 to	 characterise	 small	 peptide	
fragments.	We	had	previously	used	papain	to	digest	IgGs	to	obtain	
Fabs,1,	 10	 but	 recognised	 that	 proteolytic	 digestion	 of	 different	
antibody	subclasses	and	motifs	can	be	difficult	to	control.11			
A	second	proteolytic	enzyme	(IdeS	enzyme,	FabRICATOR®,	
Genovis)	 that	 can	 cleave	 an	 IgG	 at	 glycine-glycine	 bonds12	 in	 the	
hinge	 reagent	 to	 give	 F(ab)2	 was	 then	 examined.	 Incubation	 of	
aflibercept	 with	 IdeS	 resulted	 in	 3	 bands	 by	 SDS-PAGE	 (Figure	 2,	
lane	 3).	 New	 bands	 appeared	 at	 approximately	 30	 kDa	 and	 60-70	
kDa.	 A	 third	 band	 at	 approximately	 95-100	 kDa	 in	 this	 gel	 was	
thought	 to	be	undigested	aflibercept.	 The	 lower	molecular	weight	
fragment	at	30	kDa,	which	is	thought	to	be	the	cleaved	Fc,	and	the	
band	 for	 undigested	 aflibercept	 were	 removed	 by	 eluting	 the	
digestion	 mixture	 over	 a	 column	 that	 binds	 to	 the	 Fc	 domain	
(CaptureSelect	Midispin,	Genovis).	This	provided	a	purified	a	non-Fc	
containing	 fragment	 at	 60-70	 kDa	 (Figure	 2,	 lane	 4)	 which	 was	
thought	to	be	the	VEGFR1-VEGFR2	dimer	6	(Scheme	1B).		
Incubation	 of	 VEGFR1-VEGFR2	 dimer	 6	 with	 DTT	 caused	
this	 fragment	 to	 disappear	 to	 give	 2	 lower	molecular	weight	 frag-
ments	(Figure	2,	lane	5).	These	fragments	are	thought	to	be	the	de-
sired	VEGFR1-VEGFR2	monomer	4	(Scheme	1).	Two	bands	are	often	
observed	 after	 reduction	 of	 Fabs	 that	 are	 obtained	 by	 proteolytic	
digestion.	This	can	be	due	to	miscleavage	reactions	during	proteo-
lysis	and	may	be	exacerbated	for	aflibercept	due	to	its	difference	in	
structure	compared	to	an	IgG	and	due	to	aflibercept	glycosylation.	
There	 are	 five	 N-glycosylation	 sites	 on	 each	 monomeric	 VEGFR1-
VEGFR2-Fc	fragment	5	which	may	be	partially	or	completely	glycol-
sylated.	 There	 may	 also	 be	 additional	 heterogeneity	 caused	 by	
differences	in	saccharide	structure.	
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To	 prepare	 the	 RpR	 2,	 the	 VEGFR1-VEGFR2	 dimer	 6	 was	
first	incubated	with	DTT	for	30	minutes	to	give	the	VEGFR1-VEGFR2	
monomer	4	(Scheme	1B).	The	reaction	mixture	was	carefully	eluted	
over	 a	 PD-10	 column	 to	 remove	 the	 DTT	 while	 avoiding	 disulfide	
reformation,	and	then	the	PEG	di(mono-sulfone)	reagent	3	(derived	
from	 a	 10	 kDa	 PEG	 precursor)	 was	 added	 to	 the	 solution	 of	 the	
monomeric	 VEGFR1-VEGFR2	 4.	 Incubation	 of	 the	 reaction	 mixture	
for	3	h	(Figure	2S,	lane	1,	ESI)	was	then	followed	by	purification	by	
size	 exclusion	 chromatography	 (Figure	 2S,	 lanes	 2-10,	 ESI)	 to	 give	
the	purified	RpR	2	which	appeared	 in	 a	band	at	 approximately	70	
kDa	 (Figure	2,	 lanes	6	and	7).	Two	detection	dyes	were	used,	 first	
coomassie	blue	to	detect	protein	(lane	6)	and	then	barium	iodide	to	
detect	 the	 PEG	 (lane	 7)	 being	 conjugated	 to	 the	 protein.	 Starting	
from	0.8	mg	(in	1.0	mL)	of	VEGFR1-VEGFR2	dimer	6,	approximately	
0.16	mg	(in	0.5	mL)	of	RpR	2	was	obtained	(~	20	%	yield).	
At	25˚C	the	purified	RpR	2	displayed	a	solution	size	of	10.7	
±	 0.5	 nm	 (Pd,	 0.7	 ±	 0.1	 nm),	 which	 is	 similar	 to	 the	 starting	
aflibercept	 (10.2	 ±	 0.7	 nm;	 Pd,	 0.6	 ±	 0.1	 nm).	 The	 FpF	 antibody	
mimetics	 1	 were	 also	 a	 similar	 solution	 size	 to	 the	 corresponding	
IgG.1	This	is	in	stark	contrast	to	when	PEG	is	conjugated	only	at	one	
terminus	 to	 a	 single	 protein	 where	 the	 solution	 size	 of	 a	 PEG-
protein	conjugate	is	dominated	by	the	random	coil	nature	of	PEG.13	
When	 only	 one	 terminus	 of	 PEG	 is	 conjugated	 to	 a	 protein,	 the	
other	PEG	terminus	has	considerable	 freedom	to	allow	the	PEG	to	
maintain	a	large	solution	structure.		
As	 a	 macromolecule,	 the	 RpR	 has	 a	 protein	 at	 each	
terminus	of	the	PEG	scaffold,	which	is	analogous	to	an	A-B-A	block	
copolymer	where	it	is	known	that	the	two	functionalised	end	blocks	
can	 self-associate.14	 The	 dimeric	 VEGFR1-VEGFR2	 fragment	 6	 also	
displayed	a	solution	size	of	10.03	±	0.1	nm	(Pd,	0.7	±	0.1	nm)	which	
is	 similar	 to	 both	 aflibercept	 and	 RpR	 2.	 Interestingly,	 when	 the	
VEGFR1-VEGFR2	 fragment	6	was	treated	with	DTT	and	the	cysteine	
thiols	were	blocked	with	 iodoacetamide,	 the	cysteine	 thiol-capped	
monomeric	 VEGFR1-VEGFR2	 fragment	 7	 (Scheme	 1B)	 displayed	 a	
solution	size	of	7.2	±	0.4	nm	(Pd,	0.7	±	0.1	nm).	Although	the	dimer	
6	is	twice	the	molecular	weight	of	the	VEGFR1-VEGFR2	monomer	7,	
its	 size	 in	 solution	 is	 only	 about	 40%	 larger	 suggesting	 that	 there	
may	 be	 some	 non-covalent	 intramolecular	 association	 between	
each	of	the	VEGFR1-VEGFR2	monomers	in	the	dimer	6.		
The	binding	properties	of	the	RpR	2	and	aflibercept	were	
then	 evaluated	 by	 surface	 plasmon	 resonance	 (Biacore)	 to	
determine	 the	 affinity	 (KD),	 and	 the	 rate	 constants	 of	 association	
(ka)	 and	 dissociation	 (kd)	 (Table	 1).	 Vascular	 endothelial	 growth	
factor-165	 (VEGF165),	 which	 is	 a	 ligand	 for	 aflibercept,	 was	
immobilised	 at	 a	 density	 to	minimise	 or	 prevent	 rebinding	 events	
(91	RU).1,	15	The	dissociation	rate	(kd)	for	the	RpR	2	was	slower	than	
what	was	observed	with	aflibercept.	 Interestingly,	 the	ka	appeared	
to	 be	 slightly	 faster	 in	 RpR	 2	 compared	 to	 aflibercept.	 This	 is	 in	
contrast	to	what	was	previously	observed	for	anti-VEGF	FpF	which	
had	 a	 slower	 association	 rate	 than	 the	 precursor	 IgG	 antibody.1	
However	it	was	the	decreased	kd	of	RpR	2	that	appeared	to	be	the	
dominating	factor	to	cause	the	improved	affinity	of	RpR	2	compared	
to	aflibercept	(Table	1).	Representative	fitting	curves	for	aflibercept	
and	RpR	2	are	shown	in	the	ESI	(Figure	S3,	ESI).	
Exploiting	 reduced	 dissociation	 rates	 may	 be	 a	 viable	
strategy	 to	 increase	 efficacy	 by	 increasing	 the	 residence	 time	 and	
mode	of	action	within	specific	tissue.16	Although	the	reduction	in	kd	
for	FpF	1	is	also	slower	than	the	parent	IgG,1	there	appears	to	be	a	
greater	relative	reduction	in	kd	for	the	RpR	2	compared	to	its	parent	
Fc-fusion	(i.e.	aflibercept).	During	initial	dissociation	steps	from	the	
ligand	of	one	of	the	two	VEGFR1-VEGFR2	domains	in	the	RpR	2,	PEG	
conformational	 flexibility	may	be	more	efficient	 for	 rebinding	than	
the	 polypeptide	 linking	 the	 Fc	 domain	 to	 the	 VEGFR1-VEGFR2	
domain	 in	 aflibercept.	 This	 suggests	 there	 is	 less	 flexibility	 in	 the	
bivalent	binding	moieties	in	the	Fc-fusion	protein	(aflibercept)	than	
there	is	in	an	IgG	(e.g.	bevacizumab).			
The	 VEGF	 binding	 of	 the	 capped	 VEGFR1-VEGFR2	
monomer	 7	 (Figure	 S4,	 ESI)	 was	 reduced	 when	 compared	 to	 the	
VEGFR1-VEGFR2	 dimer	 6.	 This	 exemplified	 the	 advantages	 of	 the	
cooperative	bivalent	binding	that	is	possible	with	(i)	aflibercept,	(ii)	
the	dimeric	VEGFR1-VEGFR2	fragment	6	and	(iii)	RpR	2	(Table	1).	The	
similar	binding	properties	that	were	observed	for	both	the	dimer	6	
and	 aflibercept	 suggests	 that	 the	 placement	 of	 the	 accessible	
disulfide	bonds	linking	each	monomer	in	aflibercept	is	important	for	
the	mobility	of	the	VEGFR1-VEGFR2	binding	domains.	 Inclusion	of	a	
polypeptide	 sequence	 to	 extend	 the	 VEGFR1-VEGFR2	 receptor	
domains	 away	 from	 the	 aflibercept	 disulfide	 bonds	 to	 better	
optimise	dissociation	rates	would	be	expected	to	make	aflibercept	
less	 stable.	 Such	 an	 added	 polypeptide	 sequence	 to	 increase	 the	
flexibility	of	the	VEGFR1-VEGFR2	receptor	domains	would	invariably	
lack	secondary	structure	in	a	similar	way	to	the	hinge	region	of	IgG	
antibodies.	While	 the	 hinge	 region	 in	 IgG	 antibodies	 provides	 the	
flexibility	 needed	 for	 cooperative	 and	 bivalent	 binding	 of	 both	
Fabs,17	 the	 IgG	hinge	 region	 is	 also	 vulnerable	 to	degradation	 and	
disulfide	 scrambling.18	 The	 stable	 conjugation	 imparted	 by	 PEG-
di(mono-sulfone)	 3	 and	 use	 of	 a	 PEG	 scaffold	 provides	 enough	
flexibility	 of	 the	 VEGFR1-VEGFR2	 binding	 moieties	 to	 potentially	
maximise	 both	 association	 and	 dissociation	 rates	 that	 could	 be	
important	in	the	development	of	new	therapeutics.			
Sample	
ka	
(×105)	M-1s-
1	
kd	
(×	10-4)	s-1	
KD	
(kd/ka)	nM	
Aflibercept	 0.88	 4.20	 4.78	
(VEGFR1-VEGFR2)2	6	 1.20	 5.20	 4.30	
RpR	2	 1.13	 1.90	 1.71	
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RpR	2	was	then	evaluated	in	vitro	using	a	human	umbilical	
vein	 endothelial	 cell	 (HUVEC)	 co-culture	 (Figure	 3).	 This	 assay	
measures	 the	 migration	 and	 the	 formation	 of	 an	 anastomosing	
network	 that	 is	 characterised	 by	 tubule	 and	 junction	 formation	
during	HUVEC	 proliferation.	 These	 processes	 are	 characteristic	 for	
angiogenesis	 and	 are	 often	 a	 good	 in	 vitro	 measurement	 for	
angiogenesis.19	RpR	2	and	aflibercept	were	incubated	with	VEGF165	
at	different	molar	ratios	of	3.0,	1.5,	0.5	for	2	hours	at	370C	prior	to	
incubation	with	HUVECs.	 VEGF165	 and	 anti-mouse	 TNF-α	 IgG	were	
used	 for	 positive	 controls.	 Images	 were	 obtained	 after	 fixing	
HUVECs	 with	 an	 anti-CD31	 antibody	 to	 differentiate	 between	 the	
endothelial	 tubular	 network	 and	 non-endothelial	 structures	 of	
similar	apparent	morphology	(Figure	3A).	These	images	suggest	that	
both	aflibercept	and	RpR	2	have	similar	anti-angiogenic	properties.	
Quantification	 of	 tubule	 (Figure	 S5,	 ESI)	 and	 junction	 formation	
(Figure	3B)	 (AngioSys	 Image	Analysis	Software,	TCS	Cellworks	Ltd.)	
showed	 that	 the	 formation	 of	 these	 structures	 were	 similarly	
inhibited	in	a	concentration	dependent	manner	by	both	RpR	2	and	
aflibercept.		
To	 summarise,	 a	 new	 antibody	 Fc-fusion	 mimetic	 called	
an	 RpR	 was	 prepared.	 Aflibercept	 is	 a	 clinically	 used	 Fc-fusion	
protein	 that	 targets	 VEGF	 was	 used	 for	 these	 studies.	 Proteolytic	
digestion	 of	 aflibercept	 followed	 by	 incubation	with	DTT	 provided	
the	monomeric	VEGFR1-VEGFR2	domain	4	that	was	then	conjugated	
to	 the	PEG-di(mono-sulfone)	3	by	disulfide	bridging	conjugation	 to	
give	 the	 anti-VEGF	 RpR	 2.	 The	 strategy	 to	 proteolytically	 digest	
aflibercept	 provided	 the	means	 to	 compare	 the	 properties	 of	 the	
RpR	Fc-fusion	mimetic	2	with	aflibercept.	The	solution	size	of	RpR	2	
and	 its	 in	 vitro	 activity	 are	 comparable	 to	 aflibercept.	 Of	 most	
interest	 is	 that	binding	studies	show	that	RpR	2	has	higher	affinity	
for	 VEGF	 compared	 to	 aflibercept	 primarily	 due	 to	 a	 slower	
dissociation	 rate.	 Antibody	 based	 mimetics	 such	 as	 RpR	 2	 have	
potential	for	development	as	stable,	organ	specific	therapeutics.			
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